Janssen Korea to market Remicade

Published: 2011-07-01 06:59:00

Updated: 2011-07-01 06:59:00

Starting in July 1, Janssen Korea will have a marketing right for Remicade as a high-stake fight between Merck and Johnson & Johnson over the rights to a pair of lucrative arthritis medicines - Remicade and Simponi - was finally resolved in April.

Under the deal, Merck will relinquish exclusiv...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK